- |||||||||| Review, Journal: Serine and one-carbon metabolism, a bridge that links mTOR signaling and DNA methylation in cancer. (Pubmed Central) - Jun 29, 2020
Mammalian / mechanistic target of rapamycin (mTOR) is a critical sensor of environmental cues that regulates cellular macromolecule synthesis and metabolism in eukaryotes...Based on the latest understanding regarding the regulation of metabolic processes by mTOR signaling as well as interaction between metabolism and epigenetics, we further discuss how serine and one-carbon metabolism may serve as a bridge that links mTOR signaling and DNA methylation to promote tumor growth. Elucidating their relationship may provide novel insight for cancer therapy in the future.
- |||||||||| Afinitor (everolimus) / Novartis
Preclinical, Journal: Ultrastructure and inter-cellular contact-mediated communication in cultured human early stage follicles exposed to mTORC1 inhibitor. (Pubmed Central) - Jun 28, 2020
Recent findings demonstrate that everolimus (EVE), an mTORC1 inhibitor, limits primordial follicle activation...Given that EVE-treated follicles were smaller than controls, these findings suggest that EVE might facilitate the establishment of appropriate intercellular communications without impairing follicle ultrastructure. Therefore, mTORC1 inhibitors might represent an attractive tool to delay the culture-induced primordial follicle activation while maintaining follicles in a functionally integrated state.
- |||||||||| Avastin (bevacizumab) / Roche, everolimus / Generic mfg., paclitaxel / Generic mfg.
Retrospective data, Review, Journal: Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. (Pubmed Central) - Jun 26, 2020
Moreover, no chemotherapy regimen with or without targeted therapy is significantly better than CDK4/6 inhibitors plus hormone therapies in terms of progression-free survival. Our data support treatment guideline recommendations involving the new combinations of hormone therapies plus targeted therapies as first-line or second-line treatments, or in both settings, in women with hormone-receptor-positive, HER2-negative metastatic breast cancer.
- |||||||||| avutometinib (VS-6766) / Verastem
Enrollment open, Combination therapy: DDU RAF/MEK: Phase I Trial of VS-6766 Alone and in Combination With Everolimus (clinicaltrials.gov) - Jun 25, 2020
P1, N=94, Recruiting,
Our data support treatment guideline recommendations involving the new combinations of hormone therapies plus targeted therapies as first-line or second-line treatments, or in both settings, in women with hormone-receptor-positive, HER2-negative metastatic breast cancer. Active, not recruiting --> Recruiting
- |||||||||| letrozole / Generic mfg., everolimus / Generic mfg.
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Bolero-4: Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - Jun 24, 2020
P2, N=202, Active, not recruiting,
Active, not recruiting --> Recruiting Trial completion date: Jun 2020 --> Sep 2020 | Trial primary completion date: Jun 2020 --> Sep 2020
- |||||||||| leucovorin calcium / Generic mfg., fluorouracil / Generic mfg., Afinitor (everolimus) / Novartis
[VIRTUAL] Carcinoid Causing Catastrophic Calcemia () - Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_2432;
He was switched to Everolimus but did not respond to that and was readmitted mere weeks later for symptomatic hypercalcemia and a combination of Folinic acid, Fluorouracil, and Oxaliplatin (Folfox) was started...This patient had a rare tumor, producing an uncommon hormone, and required extensive treatment. This case shows the importance of a multidisciplinary approach in patients with hypercalcemia secondary to carcinoid tumors but refractory to traditional therapy.
- |||||||||| olanzapine / Generic mfg., Afinitor (everolimus) / Novartis
[VIRTUAL] A Rare Case of Metastatic Insulinoma in a Patient with Huntington’s Disease () - Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_2300;
She has no history of diabetes, and only home medication is Zyprexa...Patient remains on Octreotide LAR injection every 4 weeks...Other treatment modalities include injection of octreotide, EUS-aided alcohol ablation, radio-frequency ablation or embolization of insulinoma, as well as targeted therapy with everolimus or sunitinib...Diagnosis of insulinoma is often delayed or missed as symptoms may be attributed to psychiatric, cardiac or neurological disorders or medication misuse. Clinicians should be aware of insulinoma as a cause of life-threatening hypoglycemia.
- |||||||||| Journal, IO Biomarker: Polyphyllin VI, a saponin from Trillium tschonoskii Maxim. induces apoptotic and autophagic cell death via the ROS triggered mTOR signaling pathway in non-small cell lung cancer. (Pubmed Central) - Jun 19, 2020
The apoptotic cell death induced by PPVI was confirmed, and it was significantly suppressed by the overexpression of AKT, ERK and mTOR, and the induced autophagic cell death which was depended on the Atg7 was decreased by the inhibitors, such as LY294002 (LY), Bafilomycin A1 (Baf), Compound C (CC) and SBI-0206965 (SBI)...Finally, the anti-tumor growth activity of PPVI in vivo was validated in A549 bearing athymicl nude mice. Taken together, our data have firstly demonstrated that PPVI is the main component in TTM that exerts the anti-proliferative effect by inducing apoptotic and autophagic cell death in NSCLC via the ROS-triggered mTOR signaling pathway, and PPVI may be a promising candidate for the treatment of NSCLC in future.
- |||||||||| Cotellic (cobimetinib) / Exelixis, Roche, Tecentriq (atezolizumab) / Roche
Trial initiation date, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker, Metastases: MEGALiT: A MolEcularly Guided Anti-Cancer Drug Off-Label Trial (clinicaltrials.gov) - Jun 18, 2020
P2, N=154, Not yet recruiting,
Taken together, our data have firstly demonstrated that PPVI is the main component in TTM that exerts the anti-proliferative effect by inducing apoptotic and autophagic cell death in NSCLC via the ROS-triggered mTOR signaling pathway, and PPVI may be a promising candidate for the treatment of NSCLC in future. Initiation date: Apr 2020 --> Sep 2020
- |||||||||| Journal, Adverse events: Analysis of drug-induced interstitial lung disease using the Japanese Adverse Drug Event Report database. (Pubmed Central) - Jun 13, 2020
Our results showed that patients who receive gefitinib or erlotinib should be closely monitored for the development of drug-induced interstitial lung disease within a short duration (4 weeks). In addition, elderly people who receive amiodarone or sho-saiko-to should be carefully monitored for the development of drug-induced interstitial lung disease.
- |||||||||| Afinitor (everolimus) / Novartis
Retrospective data, Review, Journal: Efficacy and safety of everolimus treatment on liver transplant recipients: a meta-analysis. (Pubmed Central) - Jun 11, 2020
Although everolimus combined with reduced CNI therapy significantly improved the renal function in liver transplant recipients, it did not influence the incidence of BPAR, graft loss and death. This regimen might be associated with an increased risk of adverse events, which needs to be elucidated further.
- |||||||||| everolimus / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date: Everolimus for Children With Recurrent or Progressive Ependymoma (clinicaltrials.gov) - Jun 11, 2020
P2, N=11, Active, not recruiting,
This regimen might be associated with an increased risk of adverse events, which needs to be elucidated further. Completed --> Active, not recruiting | Trial completion date: Dec 2018 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Dec 2020
- |||||||||| Odomzo (sonidegib) / Sun Pharma
Trial completion, Trial completion date, Trial primary completion date, Combination therapy, Metastases: LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma (clinicaltrials.gov) - Jun 11, 2020
P1, N=25, Completed,
Completed --> Active, not recruiting | Trial completion date: Dec 2018 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Dec 2020 Active, not recruiting --> Completed | Trial completion date: Nov 2020 --> Jun 2020 | Trial primary completion date: Nov 2020 --> Jun 2020
- |||||||||| Afinitor (everolimus) / Novartis
Journal: Evaluating the Strength of the Association Between Industry Payments and Prescribing Practices in Oncology. (Pubmed Central) - Jun 10, 2020
It is known from prior work that oncologists tend to prescribe more of the drugs made by companies that have given them money. By combining records of industry gifts with prescribing records, this study identifies the consistency of payments over time, the dollar value of payments, and payments for compensation as factors that may strengthen the association between receiving payments and increased prescribing of that company's drug.
- |||||||||| letrozole / Generic mfg., everolimus / Generic mfg.
Trial completion date, Trial primary completion date, Metastases: Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer (clinicaltrials.gov) - Jun 9, 2020
P2, N=42, Active, not recruiting,
By combining records of industry gifts with prescribing records, this study identifies the consistency of payments over time, the dollar value of payments, and payments for compensation as factors that may strengthen the association between receiving payments and increased prescribing of that company's drug. Trial completion date: Apr 2021 --> Apr 2022 | Trial primary completion date: Apr 2020 --> Apr 2021
- |||||||||| Xtandi (enzalutamide capsule) / Pfizer, Astellas
Trial completion date, Trial primary completion date, Metastases: Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer (clinicaltrials.gov) - Jun 9, 2020
P1, N=38, Active, not recruiting,
Trial completion date: Apr 2021 --> Apr 2022 | Trial primary completion date: Apr 2020 --> Apr 2021 Trial completion date: Jan 2020 --> Jan 2021 | Trial primary completion date: Jan 2020 --> Jan 2021
- |||||||||| Torisel (temsirolimus) / Pfizer, Zelboraf (vemurafenib) / Roche
Trial completion, Trial completion date, Trial primary completion date, Combination therapy, Metastases: Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer (clinicaltrials.gov) - Jun 4, 2020
P1, N=27, Completed,
Recruiting --> Completed | Trial completion date: Apr 2019 --> May 2020 | Trial primary completion date: Dec 2018 --> Jun 2019 Active, not recruiting --> Completed | Trial completion date: Dec 2020 --> Jun 2020 | Trial primary completion date: Dec 2020 --> Jun 2020
- |||||||||| Lumakras (sotorasib) / Amgen
Trial primary completion date, Combination therapy, Monotherapy, PD(L)-1 Biomarker, IO biomarker, Metastases: CodeBreak101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (clinicaltrials.gov) - Jun 4, 2020
P1b, N=430, Recruiting,
Active, not recruiting --> Completed | Trial completion date: Dec 2020 --> Jun 2020 | Trial primary completion date: Dec 2020 --> Jun 2020 Trial primary completion date: Jun 2022 --> Feb 2026
- |||||||||| Imlygic (talimogene laherparepvec) / Amgen, Afinitor (everolimus) / Novartis
Preclinical, Journal, IO Biomarker: The Oncolytic Herpes Simplex Virus Talimogene Laherparepvec Shows Promising Efficacy in Neuroendocrine Cancer Cell Lines. (Pubmed Central) - May 31, 2020
Moreover, virostatic effects of ganciclovir (GCV) on replication of T-VEC were assessed and electron microscopic pictures were taken to comprehend viral envelopment and details of the replication cycle of T-VEC in human neuroendocrine cancer...On the other hand, GCV was shown to be able to limit replication of T-VEC, thus establishing an important safety feature for future treatments of NET/NEC patients. Taken together, T-VEC opens up a promising novel treatment option for NET/NEC patients, warranting its further preclinical and clinical development.
|
